GlassScriptPhysician profile
Igor Zakharov
NPI 1043389539
$9,928.95
in general payments reported to CMS, 2019-2025
35 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $915 · 2021: $1,803 · 2022: $1,772 · 2023: $1,456 · 2024: $1,890 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,848.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.08 | 2019-2025 | Ubrelvy, Qulipta, Mavyret |
| Astrazeneca Pharmaceuticals LP | $796.58 | 2019-2025 | Breztri, Farxiga |
| Amgen INC. | $775.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $524.53 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $522.95 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $512.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $498.04 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $491.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $417.35 | 2019-2025 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $411.33 | 2021-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $361.77 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $336.64 | 2024-2025 | Zenpep |
| Horizon Therapeutics Plc | $310.66 | 2019-2022 | |
| Axsome Therapeutics, INC. | $283.16 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.86 | 2019-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $261.22 | 2019-2024 | Mounjaro |
| Sumitomo Pharma America, INC. | $196.19 | 2023-2025 | Gemtesa |
| Allergan, INC. | $162.23 | 2019-2020 | |
| Ardelyx, INC. | $140.08 | 2024-2025 | Ibsrela |
| Pfizer INC. | $139.31 | 2019-2023 | |
| Cumberland Pharmaceuticals, INC. | $130.82 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $120.70 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $88.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.26 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $73.27 | 2021-2022 | |
| Vivus LLC | $71.57 | 2020-2023 | Pancreaze |
| Takeda Pharmaceuticals U.S.A., INC. | $66.14 | 2020 | |
| Philips North America LLC | $57.82 | 2021 | |
| Exact Sciences Corporation | $56.25 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.16 | 2021-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $31.42 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.92 | 2024 | Voquezna |
| Astellas Pharma US INC | $23.33 | 2021 | |
| Covis Pharma Gmbh | $22.80 | 2022 | |
| Verona Pharma, INC. | $21.72 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Zakharov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.